한글목차

아페레시스 시장 규모는 2023년 22억 3,066만 달러에서 예측 기간 동안 CAGR 8.75%로 추이하고, 2030년에는 36억 7,155만 달러 규모로 성장할 것으로 예측됩니다.

면역 혈소판 감소증(ITP) 및 혈우병과 같은 만성 질환의 유병률 증가, 제품 개발 활동 활성화, 바이오 제약 회사의 원혈장 수요 증가가 예측 기간 동안 전체 시장 성장 에 기여할 전망입니다.

아페레시스: 시장 역학

2022년 National Organization for Rare Disorders에 따르면, 면역성 혈소판 감소증(ITP) 3개월의 유아부터 100세 이상의 노인에 이르기까지 모든 연령대의 사람들이 병에 걸릴 수 있다고 보고되었습니다. 전 세계적으로 20만 명 이상이 이 질환을 앓고 있는 것으로 추정됩니다.

World Federation of Haemophilia(2022년) 보고에 따르면 세계에서 매년 약 20,000명이 혈우병을 발병하고 있으며, 그 중 약 7,000명이 중증으로 분류되고 있습니다. 그 내역은 혈우병 A가 18만 5,318명, 혈우병 B가 3만 7,998명이라고 합니다.

면역성 혈소판 감소증(ITP) 과 혈우병과 같은 만성 혈액 질환의 유병률 증가는 아페레시스를 포함한 고급 치료 옵션 수요를 촉진하고 있습니다. 출혈성 합병증과 면역 기능 장애를 관리하고 환자의 결과를 개선하기위한 귀중한 치료법입니다.

지역별로는 북미가 큰 수익 점유율을 차지한다고 추산되고 있습니다. 제공과 같은 여러 요인으로 인한 것으로 간주됩니다.

이 보고서는 세계의 친환경 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법 규제 환경, 시장 규모 추이/예측, 각종 구분/지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 아페레시스 시장 보고서 : 인트로덕션

• 조사 범위
• 시장 분류
• 시장의 상정

제2장 아페레시스 시장 : 주요 요약

• 시장 개요

제3장 경쟁 구도

제4장 규제 분석

• 미국
• 유럽
• 일본
• 중국

제5장 아페레시스 시장 : 주요 요인 분석

• 시장 성장 촉진요인
  • 만성질환의 이환율 증가
  • 세계에서 제품 개발 활동이 증가
  • 바이오 의약품 기업으로부터의 원료 혈장 수요 증가
• 시장 성장 억제요인과 과제
  • 아페레시스 프로세스의 높은 비용
  • 아페레시스 프로세스에 따른 위험
• 시장 기회
  • 소아용으로 특별히 설계된 새로운 아페레시스 치료법의 혁신과 연구 개발의 급증
  • 지단백질 성분 제거 요법의 비용 절감과 치료법의 보급

제6장 아페레시스 시장 : Porter's Five Forces 분석

제7장 아페레시스 시장 평가

• 제품 유형별
  • 아페레시스 장치
  • 일회용
• 기술별
  • 원심 분리
  • 막 여과
• 처치별
  • 백혈구 제거 요법
  • 혈장 교환
  • 혈소판 성분 채취
  • 적혈구 제거 요법
  • 기타
• 용도별
  • 신장 질환
  • 혈액 질환
  • 신경질환
  • 자가면역질환
• 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제8장 아페레시스 시장 : 기업?제품 프로파일

• B. Braun Melsungen AG
• Asahi Kasei Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Terumo Corporation
• Baxter
• Kaneka Corporation
• Sumitomo Bakelite Company Limited
• Medica SPA
• Nikkiso Co., Ltd.
• Cerus Corporation
• Miltenyi Biotec BV & Co. KG
• Haier Inc.
• Otsuka Holdings

제9장 KOL의 견해

제10장 프로젝트 접근법

제11장 DelveInsight 정보

제12장 면책사항 및 문의

영문목차

Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders, and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing prevalence of chronic disorders and increasing product developmental activities around the world

The apheresis market was valued at USD 2,230.66 million in 2023 and is estimated to grow at a CAGR of 8.75% during the forecast period from 2024 to 2030 to reach USD 3,671.55 million by 2030. The market is experiencing significant growth due to the increasing prevalence of different types of chronic disorders like immune thrombocytopenia (ITP) and hemophilia among the population, rising product developmental activities, and rising demand for source plasma from biopharmaceutical companies acting as major factors contributing to the overall growth of the apheresis market during the forecast period from 2024 to 2030.

Apheresis Market Dynamics:

The National Organization for Rare Disorders in 2022, stated that immune thrombocytopenia (ITP) can affect individuals of all ages, ranging from as young as 3 months to over 100 years old. Approximately 40% of those diagnosed with ITP are children under the age of 10. Globally, it is estimated that more than 200,000 people are affected by this condition.

According to the World Federation of Haemophilia (2022) reports, approximately 20,000 people with hemophilia are born each year worldwide, with about 7,000 of these cases being classified as severe. In addition to this, the source further stated that there are 233,577 individuals with hemophilia, comprising 185,318 with Hemophilia A and 37,998 with Hemophilia B.

The rising prevalence of chronic hematological disorders like immune thrombocytopenia (ITP) and hemophilia is driving the demand for advanced treatment options, including apheresis. Apheresis offers targeted removal or replacement of blood components, making it a valuable therapy for managing bleeding complications, immune dysfunction, and improving patient outcomes. Additionally, the global disparities in access to clotting factors highlight the need for alternative therapeutic modalities like apheresis, further expanding its market potential.

Various product development activities by key market players will further boost the market for the same. For instance, in May 2021, Baxter International Inc. announced the global launch of PrisMax 2, the latest version of the company's next-generation platform. PrisMax 2 is designed for therapeutic plasma exchange therapy and other organ support therapies while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU).

Hence, the interplay of all the above-mentioned factors is expected to drive the apheresis market during the given forecast period from 2024 to 2030.

However, the high cost involved in the apheresis process, risks associated with the apheresis process, and others may restrict the market growth for the apheresis market.

Apheresis Market Segment Analysis:

Apheresis Market by Product Type (Apheresis machines and Disposables), Technology (Centrifugation and Membrane filtration), Procedure (Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Others), Application (Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders, and Others), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the apheresis market, the disposables category is expected to have a significant revenue share in the year 2023. This can be attributed to the increased consumption of disposables in the process of apheresis.

The disposables present in apheresis machines are manufactured and designed exclusively for one-time use, to ensure contamination-free transfer of blood components and maintain sterile conditions. Disposables form a key component for any apheresis system to deliver quality treatment, because of which all the key market players ensure a strong disposable kit profile for their apheresis systems. The Plasmat Futura Kit from B. Braun Melsungen AG, LIFE 21(R) and LIFE 18(TM) apheresis unit's disposables from Miltenyi Biotec, the disposable TPE 2000 Set for PRISMAFLEX System from Baxter are some of the examples of quality disposables manufactured by key companies to build and flourish their market for apheresis.

Therefore, the widespread uses and various advantages of the disposables category that enhance performance and usability, solidify a significant impact on the growth of the overall apheresis market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall apheresis market:

Among all the regions, North America is estimated to hold a significant revenue share in the apheresis market. This can be attributed to several factors such as rising cancer cases and Guillain-Barre Syndrome (GBS), continuous product developmental strategies by regulatory bodies, that offer improved treatment features and efficiency, that act as key factors contributing to the growth of the apheresis market in the North America region during the forecast period from 2024 to 2030.

As per figures directed by the Globocan 2024, it indicated that in the year 2022 Leukemia affected 63,144 people in the US, whereas in Canada leukemia affected about 8,503 people. The same source also mentioned that by the year 2045, leukemia will afflict about 101 thousand people in the North America region. As leukemia cases rise, apheresis is increasingly utilized for managing complications like hyperleukocytosis and for collecting stem cells for transplants and thereby the market for the same is increased.

According to data from the Centers for Disease Control and Prevention (2023), it stated that Guillain-Barre Syndrome (GBS) is a rare disorder in which the body's immune system mistakenly attacks the peripheral nerves. This damage to the nerves leads to muscle weakness and, in some cases, paralysis. The exact cause of GBS is not fully understood, but it frequently occurs following an infection with a virus or bacteria. In the United States, an estimated 3,000 to 6,000 people develop GBS each year. Apheresis plays a critical role in treating autoimmune disorders like Guillain-Barre Syndrome by removing harmful antibodies. Thus the rising clinical reliance highlights the expanding market for apheresis systems and services.

Various product developmental strategies such as clearances by regulatory authorities in the region play a major role in pushing forward the revenue shares of apheresis. For example, in August 2023, Terumo Blood and Cell Technologies (Terumo BCT) announced the U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole blood into platelets and other components in a single centrifugation cycle.

Moreover, product launches by key market players in the region are further expected to propel the growth of the North America apheresis market.

Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the apheresis market during the forecast period from 2024 to 2030.

Apheresis Market key players:

Some of the key market players operating in the apheresis market include B. Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V. & Co. KG, Haier Inc., Otsuka Holdings, and others.

Recent Developmental Activities in the Apheresis Market:

• In September 2023, Sanguine Biosciences (Sanguine), a leader in connecting patients with biomedical researchers to accelerate precision medicine R&D, announced the opening of a blood donor center in Los Angeles. The center specialized in collecting concentrated white blood cell biospecimens through apheresis.
• In June 2022, Terumo Blood and Cell Technologies, a medical technology company specializing in products, software, and services for blood component collection, therapeutic apheresis, and cellular technologies, announced that NHS England selected the automated red blood cell exchange (RBCX) procedure, performed using the company's Spectra Optia(R) Apheresis System, through the NHS MedTech Funding Mandate (MTFM) for treating sickle cell disease.

Key takeaways from the Apheresis market report study

• Market size analysis for current apheresis market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the apheresis market
• Various opportunities available for the other competitors in the apheresis market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current apheresis market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for apheresis market growth in the coming future?

Target audience who can be benefited from this Apheresis market report study

• Apheresis device providers
• Research organizations and consulting companies
• Apheresis-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in apheresis
• Various end-users who want to know more about the apheresis market and the latest developments in the apheresis market

Frequently Asked Questions for the Apheresis Market:

1. What are apheresis?

• The apheresis is a medical technology used to separate various constituents of the blood, in which the remaining components of the blood are returned to the patient after extraction of the desired component (viz. erythrocytes, leukocytes, plasma, platelets etc.).

2. What is the market for apheresis?

• The apheresis market was valued at USD 2,230.66 million in 2023 and is estimated to grow at a CAGR of 8.75% during the forecast period from 2024 to 2030 to reach USD 3,671.55 million by 2030.

3. What are the drivers for the apheresis market?

• The market is experiencing significant growth due to the increasing prevalence of different types of chronic disorders like immune thrombocytopenia (ITP) and hemophilia among the population, rising product developmental activities, and rising demand for source plasma from biopharmaceutical companies that are acting as major factors contributing to the overall growth of the apheresis market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the apheresis market?

• Some of the major market players operating in the apheresis market include B. Braun Melsungen AG, Asahi Kasei Corporation, Fresenius Kabi AG, Haemonetics Corporation, Terumo Corporation, Baxter, Kaneka Corporation, Sumitomo Bakelite Company Limited, Medica SPA, Nikkiso Co., Ltd., Cerus Corporation, Miltenyi Biotec B.V. & Co. KG, Haier Inc., Otsuka Holdings, and others.

5. Which region has the highest share in the apheresis market?

• Among all the regions, North America is estimated to hold a significant revenue share in the apheresis market. This can be attributed to several factors such as rising cancer cases and Guillain-Barre Syndrome (GBS), continuous product developmental strategies by regulatory bodies, that offer improved treatment features and efficiency, which are the major key factors that contribute to the growth of the apheresis market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Apheresis Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Apheresis Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Apheresis Market Key Factors Analysis

• 5.1. Apheresis Market Drivers
  • 5.1.1. Increasing prevalence of chronic disorders
  • 5.1.2. Increasing product developmental activities around the world
  • 5.1.3. Rising demand for source plasma from biopharmaceutical companies
• 5.2. Apheresis Market Restraints and Challenges
  • 5.2.1. High cost involved in the apheresis process
  • 5.2.2. Risks associated with the apheresis process
• 5.3. Apheresis Market Opportunities
  • 5.3.1. Surge in innovation and R&D for new apheresis treatment methods specially designed for children
  • 5.3.2. Reduction in the cost of lipoprotein apheresis and widespread availability of the therapy

6. Apheresis Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Apheresis Market Assessment

• 7.1. By Product Type
  • 7.1.1. Apheresis machines
  • 7.1.2. Disposables
• 7.2. By Technology
  • 7.2.1. Centrifugation
  • 7.2.2. Membrane filtration
• 7.3. By Procedure
  • 7.3.1. Leukapheresis
  • 7.3.2. Plasmapheresis
  • 7.3.3. Plateletpheresis
  • 7.3.4. Erythrocytapheresis
  • 7.3.5. Others
• 7.4. By Application
  • 7.4.1. Renal Disorders
  • 7.4.2. Hematological Disorders
  • 7.4.3. Neurological Disorders
  • 7.4.4. Autoimmune Disorders
  • 7.4.5. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Apheresis Market Size in USD million (2021-2030)
    • 7.5.1.2. Canada Apheresis Market Size in USD million (2021-2030)
    • 7.5.1.3. Mexico Apheresis Market Size in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.2. Germany Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.4. Italy Apheresis market size in USD million (2021-2030)
    • 7.5.2.5. Spain Apheresis Market Size in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Apheresis Market Size in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.2. Japan Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.3. India Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.4. Australia Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.5. South Korea Apheresis Market Size in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia-Pacific Apheresis Market Size in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Apheresis Market Size in USD million (2021-2030)
    • 7.5.4.2. Africa Apheresis Market Size in USD million (2021-2030)
    • 7.5.4.3. South America Apheresis Market Size in USD million (2021-2030)

8. Apheresis Market Company and Product Profiles

• 8.1. B. Braun Melsungen AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Asahi Kasei Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Fresenius Kabi AG
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Haemonetics Corporation
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Terumo Corporation
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Baxter
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Kaneka Corporation
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Sumitomo Bakelite Company Limited
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Medica SPA
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Nikkiso Co., Ltd.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Cerus Corporation
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Miltenyi Biotec B.V. & Co. KG
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Haier Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Otsuka Holdings
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us